This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Chemotherapy-Induced Peripheral Neuropathy Survey

This study has been withdrawn prior to enrollment.
(Study assessment tool development delayed.)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center Identifier:
First received: November 17, 2009
Last updated: April 29, 2016
Last verified: February 2013
The goal of this research study is to learn more about pain and other symptoms that patients may experience while receiving chemotherapy treatment with platinum agents, taxanes, and/or bortezomib.

Condition Intervention
Breast Cancer Colorectal Cancer Myeloma Chemotherapy-induced Peripheral Neuropathy Behavioral: Questionnaire Behavioral: Sensory Tests Behavioral: Interview

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Chemotherapy-Induced Peripheral Neuropathy: Feasibility and Validity of New Symptom Measurement Tools in Patients on Treatment With Platinum Agents, Taxanes and Bortezomib

Resource links provided by NLM:

Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Assessment of Patient's Symptoms (Questionnaire) [ Time Frame: Each patient administered questionnaire at single point in time. ]

Enrollment: 0
Study Start Date: November 2009
Study Completion Date: February 2013
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Questionnaire + Sensory Tests + Interview Behavioral: Questionnaire
3 questionnaires to collect information about any pain and/or symptoms experienced, general well-being, and personal information such as age and marital status. One (1) will be a symptom assessment questionnaire where asked to rate symptoms on a scale of 0-10.
Other Name: Survey
Behavioral: Sensory Tests
Test of sensitivity to things such as cold and touch, involve feeling cold objects, feeling bumps on a rectangular board, and putting pegs into holes on a board; and marking on computerized drawings areas experience pain, numbness, and/or cold sensitivity.
Behavioral: Interview
First 5 patients receiving platinum agents, taxanes, and bortezomib (15 patients total) will be asked to describe their symptoms in an open-ended, semi-structured 20-30 minute interview.

  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients, age 18 years or older, receiving chemotherapy with cisplatin or oxaliplatin (platinum agents), taxanes, and/or bortezomib at UT MD Anderson Cancer Center.

Inclusion Criteria:

  1. Patients >= 18 years old.
  2. Patients must be fluent with the English language.
  3. Patients must be on chemotherapy regimes with any of the study drugs: cisplatin, oxaliplatin, taxanes and/or bortezomib.

Exclusion Criteria:

  1. Significant cognitive impairment as determined by the trained research staff
  2. Chronic alcoholism or substance abuse
  3. Diagnosis of severe depression
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01016028

Sponsors and Collaborators
M.D. Anderson Cancer Center
Principal Investigator: Charles Cleeland, PHD,BA UT MD Anderson Cancer Center
  More Information

Additional Information:
Responsible Party: M.D. Anderson Cancer Center Identifier: NCT01016028     History of Changes
Other Study ID Numbers: 2009-0439
Study First Received: November 17, 2009
Last Updated: April 29, 2016

Keywords provided by M.D. Anderson Cancer Center:
Colorectum Cancer
Colorectal disease
neuropathic symptom tool
chemotherapy-induced peripheral neuropathy
Quantitative Sensory Testing
symptom measurement tools
platinum agents

Additional relevant MeSH terms:
Colorectal Neoplasms
Peripheral Nervous System Diseases
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neuromuscular Diseases
Nervous System Diseases
Antineoplastic Agents processed this record on September 21, 2017